Overview

Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Status:
Withdrawn
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of abiraterone acetate in male Filipino patients with advanced metastatic castration resistant prostate cancer (CRPC) who have received prior chemotherapy containing a taxane.
Details
Lead Sponsor:
Janssen Pharmaceutica
Treatments:
Abiraterone Acetate
Prednisone